代谢功能障碍相关脂肪性肝病与心血管疾病风险
基于韩国全国健康筛查数据,纳入2009年接受健康体检的20-79岁成人9 775 066名,按MASLD、MetALD、MASLD合并其他病因及无MASLD/相关脂肪性肝病分为四组,脂肪肝指数≥30判定脂肪性肝病。中位随访12.3年,MASLD/相关脂肪性肝病者心血管疾病风险高于无此病者(HR 1.38,95%CI 1.37至1.39)。
要点
- MASLD、MetALD和MASLD合并其他病因的患病率分别为27.5%、4.4%和1.5%
- 无既往心血管疾病的8 808 494名参与者中位随访12.3年,发生272 863例心血管疾病事件
- MASLD/相关脂肪性肝病者心血管疾病风险高于无此病者,校正后HR 1.38(95%CI 1.37至1.39)
核心结论
- MASLD/相关脂肪性肝病在韩国成人中患病率超过三分之一,并伴随较高的心血管疾病风险。
研究设计与样本
- 基于全国健康筛查数据,纳入2009年接受健康体检的20-79岁成人9 775 066名,分为MASLD、MetALD、MASLD合并其他病因及无MASLD/相关脂肪性肝病四组,脂肪肝指数≥30判定脂肪性肝病。
主要发现
- MASLD、MetALD和MASLD合并其他病因的患病率分别为27.5%、4.4%和1.5%。
- 无既往心血管疾病的8 808 494名参与者中位随访12.3年,期间发生272 863例心血管疾病事件。
- 与无MASLD/相关脂肪性肝病者相比,MASLD/相关脂肪性肝病者心血管疾病累积发病率和多变量校正风险更高,HR 1.38(95%CI 1.37至1.39)。
- 与无相应疾病者相比,多变量校正心血管疾病事件HR(95%CI)为MASLD 1.39(1.38至1.40)、MetALD 1.28(1.26至1.30)、MASLD合并其他病因1.30(1.26至1.34)。
- 与无相应疾病者相比,代谢功能障碍相关脂肪性肝病或非酒精性脂肪性肝病参与者的心血管疾病风险也更高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We explored clinical implications of the new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing its prevalence and associated cardiovascular disease (CVD) risk. DESIGN: From nationwide health screening data, we identified 9 775 066 adults aged 20-79 who underwent health examination in 2009. Participants were categorised into four mutually exclusive groups: (1) MASLD; (2) MASLD with increased alcohol intake (MetALD); (3) MASLD with other combined aetiology (the three collectively referred to as MASLD/related steatotic liver disease (SLD)); and (4) no MASLD/related SLD. SLD was determined by fatty liver index ≥30. The primary outcome was CVD event, defined as a composite of myocardial infarction, ischaemic stroke, heart failure or cardiovascular death. RESULTS: The prevalence of MASLD, MetALD and MASLD with other combined aetiology was 27.5%, 4.4% and 1.5%, respectively. A total of 8 808 494 participants without prior CVD were followed up for a median of 12.3 years, during which 272 863 CVD events occurred. The cumulative incidence and multivariable-adjusted risk of CVD were higher in participants with MASLD/related SLD than in those without (HR 1.38 (95% CI 1.37 to 1.39)). Multivariable-adjusted HR (95% CI) of CVD events was 1.39 (1.38 to 1.40) for MASLD, 1.28 (1.26 to 1.30) for MetALD and 1.30 (1.26 to 1.34) for MASLD with other combined aetiology compared to the absence of any of these conditions. CVD risk was also higher in participants with metabolic dysfunction-associated fatty liver disease or non-alcoholic fatty liver disease than in those without the respective condition. CONCLUSION: Over one-third of Korean adults have MASLD/related SLD and bear a high CVD risk.
引用
- Lee HH, Lee HA, Kim EJ, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024. PMID: 37907259. doi:10.1136/gutjnl-2023-331003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。